Profile
Corporate information
Official name
Limula SA
Registration country
Cell therapies hold immense promise for revolutionizing medical treatment by leveraging the body's own cells to combat diseases and disorders, offering potential cures and improved outcomes for patients. However, manufacturing challenges like cost, reliability, and scalability hinder their widespread adoption. Limula is on a mission to enable a future where everyone can be treated with the most advanced therapies available, at reasonable cost, wherever they are. Their innovative solution integrates a bioreactor with a centrifuge, along with single-use kits and reagents, to automate and standardize the production of cell therapies. This unique approach streamlines the manufacturing process, reducing manual interventions and minimizing the risk of contamination, ultimately resulting in higher efficiency and lower production costs. Limula's technology also allows for scalable production, accommodating a wide range of volumes from 2 mL to 2 L, making it adaptable to various manufacturing needs.
Funding
Funding rounds
Investor | Profile | Country | Notes | |
---|---|---|---|---|
![]() |
LifeX Ventures | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
![]() |
Zühlke Group | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
![]() |
Oxford Seed Fund | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
![]() |
Lichtsteiner Foundation | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
![]() |
W.A. De Vigier Foundation | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
![]() |
Verve Capital Partners AG | Switzerland | Initial investment. Round participant. |